GeoVax Labs, Inc. (NASDAQ:GOVX) Given Average Rating of “Buy” by Brokerages

Shares of GeoVax Labs, Inc. (NASDAQ:GOVX) have received an average rating of “Buy” from the seven analysts that are presently covering the stock, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $14.20.

Separately, D. Boral Capital reiterated a “buy” rating and set a $18.00 price objective on shares of GeoVax Labs in a research report on Friday, March 28th.

GeoVax Labs Trading Up 7.2 %

Shares of GOVX opened at $1.04 on Thursday. The firm has a fifty day simple moving average of $1.47 and a two-hundred day simple moving average of $2.01. GeoVax Labs has a 1-year low of $0.88 and a 1-year high of $11.18. The firm has a market cap of $14.39 million, a PE ratio of -0.18 and a beta of 3.70.

GeoVax Labs (NASDAQ:GOVX) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.49. The firm had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $2.38 million. As a group, research analysts forecast that GeoVax Labs will post -4.49 EPS for the current fiscal year.

Institutional Trading of GeoVax Labs

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC acquired a new position in GeoVax Labs in the 3rd quarter worth about $97,000. Citadel Advisors LLC purchased a new stake in GeoVax Labs during the 4th quarter valued at about $104,000. Northern Trust Corp acquired a new stake in shares of GeoVax Labs in the fourth quarter valued at approximately $29,000. Finally, Geode Capital Management LLC increased its stake in shares of GeoVax Labs by 59.0% in the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock worth $223,000 after acquiring an additional 33,440 shares during the last quarter. Institutional investors and hedge funds own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.